铂抗肿瘤药米铂的合成

王庆琨,周利民,普绍平,黄天俊,温志寿,王蒙

中国药学杂志 ›› 2013, Vol. 48 ›› Issue (18) : 1594-1595.

PDF(390 KB)
PDF(390 KB)
中国药学杂志 ›› 2013, Vol. 48 ›› Issue (18) : 1594-1595. DOI: 10.11669/cpj.2013.18.020
论著

铂抗肿瘤药米铂的合成

  • 王庆琨1,周利民2,普绍平1,黄天俊1,温志寿1,王蒙1
作者信息 +

Synthesis of Miriplatin, A Novel Platinum-Based Antitumor-Drug

  • WANG Qing-kun1,ZHOU Li-min2,PU Shao-ping1,HUANG Tian-jun1,WEN Zhi-shou1,WANG Meng1
Author information +
文章历史 +

摘要

目的合成铂类抗肿瘤新药米铂。方法以K4PtCl4为起始原料,将与亚硝酸钠反应生成的K4Pt(NO2)4溶液,与(1R,2R)-1,2-环己二胺反应生成顺式-二硝基-(1R,2R)-1,2-环己二胺合铂(II),使用硫酸肼还原NO2-根后将得到的溶液与正十四碳酸钠的正丁醇溶液反应生成米铂。采用元素分析、质谱、红外光谱、核磁共振氢谱、热分析和比旋光度对其结构进行表征。结果合成的化合物结构与标题化合物一致,产率约61%。结论本方法为米铂的合成提供了一条新型的工艺路线。

Abstract

OBJECTIVE To synthesize the platinum-based anti-tumor drug miriplatin. METHODS Miriplatin was synthesized from K4PtCl4. K4PtCl4was reacted with sodium nitrite to give the K4Pt(NO2)4 solution which reacted with(1R,2R)-1,2-cyclohexanediamine thus resulting in the key intermediate Pt(C6H14N2)(NO2)2. The key intermediate was subsequently reacted with hydrazine sulfate and sodium myristate in n-butanol to give the target compound. The structure of the target compound was identified by elemental analysis, ESI-MS, FT-IR, 1H-NMR, thermal analysis and specific optical rotation measurement. RESULTS The structure of the synthesized compound was consistent with the title compound, and the yield was about 61%. CONCLUSION This study provides a novel synthesis process for miriplatin.

关键词

化学合成 / 抗肿瘤药物 / 米铂

Key words

chemical synthesis / antitumor drug / miriplatin

引用本文

导出引用
王庆琨,周利民,普绍平,黄天俊,温志寿,王蒙. 铂抗肿瘤药米铂的合成[J]. 中国药学杂志, 2013, 48(18): 1594-1595 https://doi.org/10.11669/cpj.2013.18.020
WANG Qing-kun,ZHOU Li-min,PU Shao-ping,HUANG Tian-jun,WEN Zhi-shou,WANG Meng. Synthesis of Miriplatin, A Novel Platinum-Based Antitumor-Drug[J]. Chinese Pharmaceutical Journal, 2013, 48(18): 1594-1595 https://doi.org/10.11669/cpj.2013.18.020
中图分类号: R97   

参考文献

TAKUJI O, SHUICHI O, TOSHIO N, et al. Phase Ⅱ trial of inra-arterial chemotherapy using a novel lipophilic platinum derivative(SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs, 2004, 22(2):169-176. KISHIMOTO S, NOGUCHI T, YAMAOKA T, et al. In vitro release of SM-11355,cis-platinum(Ⅱ) suspended in Lipiodol. Biol Pharm Bull, 2000, 23(5): 637-640. MAEDA M, SASAKI T. Liposoluble platinum(Ⅱ) complex and preparation thereof: EP, 0193936(B1). 1986-03-05. TANNO N, KISHIMOTO H, NAKATSU M. Fat soluble platinum(ii) complex hydrate:JP, 11315088(A). 1999-11-16. YOKOYAMA T, KISHIMOTO H. Method for preparing platinum complex: JP, 2004083508(A). 2004-03-18. WANG Q K, PU S P, LUAN C F, et al. Synthesis and structural characterization of miriplatin,a platinum-based anti-tumor drug. Chin New Drugs J(中国新药杂志), 2011, 20(17): 1715-1717. WANG Q K, PU S P, ZHU Z B, et al. A new synthetic method and characterization of miriplatin,an antitumor drug. Chin J Med Chem(中国药物化学杂志), 2011, 21(3): 213-215. WANG Q K, PU S P, ZHU Z B, et al. Improved synthesis of miriplatin,an antitumor drug. Chin J Med Chem(中国药物化学杂志), 2012, 22(1): 36-37.

基金

云南省科技计划项目(2010DH021);昆明市五华区科技计划项目(201037)
PDF(390 KB)

Accesses

Citation

Detail

段落导航
相关文章

/